An increased risk of differentiated thyroid carcinoma in Iran with the 677C→T homozygous polymorphism in the MTHFR Gene

Cancer Epidemiol. 2011 Feb;35(1):56-8. doi: 10.1016/j.canep.2010.10.001. Epub 2010 Nov 2.

Abstract

Background: Methylenetetrahydrofolate reductase (MTHFR) involves in folic acid metabolism which influences DNA methylation. A single nucleotide polymorphism (SNP) called 677C→T in MTHFR gene causes producing a thermolabile enzyme with reducing function and eventually defects DNA methylation. To determine association between germ-line polymorphism in MTHFR gene with differentiated thyroid carcinoma (DTC), this preliminary study was designed.

Methods: This was a case-control study of 154 DTC patients and 198 cancer free individuals. Genotyping was performed by a multiplex PCR method and the frequencies of the 677C→T SNP in cases and controls were compared. The risk estimation was done by multivariate logistic regression analysis.

Results: Compared to CC genotype, an increased risk of DTC for the 677C→T homozygous genotype was demonstrated (odds ratio [OR]: 2.08, 95% confidence interval [CI]: 0.82-5.25). Also, multivariate analysis demonstrated an increased risk of DTC in recessive fashion (TT vs. CC or CT) (OR: 2.38, 95% CI: 0.97-5.82).

Conclusion: The MTHFR 677C→T homozygous variant allele may be associated with increased risk of DTC.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Cell Differentiation
  • Female
  • Genotype
  • Homozygote
  • Humans
  • Iran / epidemiology
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Middle Aged
  • Polymorphism, Single Nucleotide / genetics*
  • Risk Factors
  • Thyroid Neoplasms / epidemiology
  • Thyroid Neoplasms / genetics*

Substances

  • Methylenetetrahydrofolate Reductase (NADPH2)